Lawmakers ban common items typically found in hotels and restaurants: 'The focus must now shift to implementation'
According to a press release from the Council of the EU, the new rules will drastically reduce single-use plastic packaging and set mandatory goals for companies to sell some of their products in reusable packaging.
The packaging mandates will require businesses to package their products with a minimum percentage of recycled content by 2030 and up to 65% for single-use plastic bottles by 2040. Businesses will also have to minimize packaging materials and harmful substances, such as perfluoroalkyl and polyfluoroalkyl substances, in food packaging if they exceed safe limits.
Restrictions on single-use plastic packaging include the following products: prepacked fruits and vegetables weighing less than 3.3 pounds; foods and drinks, including individual portions of sugar, creamer, sauces, and condiments, offered in hotels, restaurants, and bars; travel-sized toiletry products used in the hospitality industry; and some single-use plastic bags at grocery stores.
As for reuse targets, the Council of the EU stated that by 2030, 40% of packaging used in the transport and sales sectors and 10% for grouped packaging must be reusable. Restaurants that offer takeout will also be required to allow customers to bring their own containers for food and drinks at no extra charge.
The packaging regulations will go into effect in August 2026, with extensions allowed for certain requirements, per Lexology.
Since plastic has been linked to numerous health problems, including reproductive issues, the rules will have a positive impact on humans.
PFAS exposure from food packaging may contribute to high cholesterol and blood pressure, increased risks of certain cancers, developmental problems, and immune suppression, according to the U.S. Food and Drug Administration. Limiting packaging that contains these harmful chemicals will make eating out a much healthier experience in the EU.
These packaging rules will also be a huge win for the environment, as the Council of the EU explained that waste produced from packaging is outpacing the amount recycled. In 2022, the EU generated nearly 410 pounds of packaging waste per person, 36% of which was plastic packaging.
When you think about a product's packaging, which of these factors is more important to you?
The way it looks
The information it provides
The waste it produces
I don't think about packaging at all
Click your choice to see results and speak your mind.
The packaging regulations should make it easier for consumers and businesses to reduce waste and live more sustainably.
"With the legislative framework completed, the focus must now shift to implementation — a critical phase that will determine the regulation's success," Francesca Stevens, secretary general of the European packaging trade group Europen, told Packaging Dive. "The upcoming secondary legislation must be precise in the way it defines obligations and consistency across related regulations. The packaging industry will play a vital role in this process."
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
We're making a batch of trades — trimming 3 stocks and buying 2 others
We are making a handful of trades on Monday: We are selling 100 shares of Abbott Laboratories at roughly $125.51. Following the trade, Jim Cramer's Charitable Trust will own 400 shares of ABT, decreasing its weighting to about 1.35% from 1.70% We are selling 100 shares of Danaher at roughly $188.79. Following the trade, the Trust will own 450 shares of DHR, decreasing its weighting to about 2.35% from 2.85%. We are selling 15 shares of Eaton at roughly $376.69. Following the trade, the Trust will own 310 shares of ETN, decreasing its weighting to about 3.20% from 3.35%. We are buying 250 shares of Cisco Systems at roughly $68.24. Following the trade, the Trust will own 800 shares of CSCO, increasing its weighting to about 1.50% from about 1%. We are buying 50 shares of TJX Companies at roughly $124.11. Following the trade, the Trust will own 800 shares of TJX, increasing its weighting to about 2.70% from about 2.50%. Abbott Labs shares have made a nice comeback over the past two sessions, recovering about half of last Thursday's sell-off in reaction to a disappointing cut to its full-year sales growth outlook . The main issue dragging the outlook was in its diagnostics business, which struggled due to the longer-than-expected "volume-based procurement" program in China, which is part of the government's national strategy to control health-care costs. It's a transitory issue, but the company said this program is going to take a couple extra quarters to work through. Given that the issue is likely to persist for several quarters, we're taking a more downbeat view on the stock and using the recent strength to trim the position. This brings us to Danaher. The company also has a big diagnostics business in China. When the company reports before the opening bell Tuesday, we expect it to acknowledge a similar headwind. An analyst at Jefferies wrote late Friday that they think the ongoing VBP program in China could negatively impact the company's full-year outlook by an incremental $30 to $40 million, on top of the $150 million hit that is currently baked into guidance. The bar into earnings for Danaher should be much easier than Abbott, since the stock of the former has been horrible this year while Abbott having a solid year into the print. However, we are trimming the position and downgrading our rating to a 2 to protect against the same problem hurting us twice. From these sales, we'll realize a solid gain of about 10% on Abbott stock purchased in March 2024, but we'll register a very disappointing loss of about 25% on Danaher stock bought in January 2022. As for Eaton, we are making a small sale to be consistent with what we said Thursday during the Morning Meeting. The stock popped about 5% that day and hit a new record high in reaction to strong earnings from its European peers in the power and electrical equipment space. The news is a positive sign for Eaton's upcoming earnings report on Aug. 5. That said, we're taking profits into the recent strength to guard against the possibility that this record rally has already priced in much of the upside. From this sale, we will realize a great gain of about 67% on stock purchased in November 2023. We're taking some of these cash proceeds to scale deeper into our newest position, Cisco Systems. We called up this networking equipment company from the Bullpen last Thursday to increase the portfolio's exposure to the technology side of the AI infrastructure buildout (Eaton, GE Vernova and to a lesser extent Dover give us exposure on the industrial side). When Cisco last reported earnings in May, it said it reached its goal of $1 billion in AI infrastructure orders from large tech customers one quarter early. Beyond AI, Cisco's shift toward subscription-based software is still underappreciated, helping lift gross margins and justifying a higher price-to-earnings valuation. Lastly, we are adding to our position in the off-price retailer TJX, the parent company of TJ Maxx, Marshalls and Home Goods. The stock has dopped about 4.5% since we sold 50 shares in April and about 6% since the company reported better-than-expected first-quarter earnings in May. We like this pullback as an opportunity to pick up more shares. Although the stock's recent performance has been lackluster, the fundamental story remains strong, with TJX catering to the value-seeking consumer and gaining share from the store closures and struggles at other department stores. (Jim Cramer's Charitable Trust is long ABT, DHR, CSCO, TJX, ETN, GEV and DOV. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
4 hours ago
- Yahoo
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Approval is based on positive results from the pivotal Phase III ARANOTE trial. This broadened indication allows doctors to use darolutamide plus ADT, with or without chemotherapy (docetaxel), enabling them to better tailor treatment plans to meet the needs of patients with mHSPC. Orion's collaboration partner Bayer announced today that the European Commission has granted marketing authorization in the European Union (EU) for darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. Darolutamide, under the brand name Nubeqa®, is already approved in over 85 countries for use with ADT and docetaxel in mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who are at high risk of developing metastatic disease. Darolutamide is developed jointly by Orion and Bayer. Prostate cancer is the second most common cancer and the fifth most common cause of cancer death in men worldwide. In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 In Europe, there were almost 474,000 estimated new cases of prostate cancer in 2022 with approximately 115,000 deaths. 2 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.3 About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is radiological progression free survival (rPFS), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in rPFS were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans, support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile, in both mHSPC registrational studies where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as a treatment for localized prostate cancer in combination with radiotherapy. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.4,5,6 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Terhi Ormio, Vice President, Communications, Orion Corporation tel. +358 10 426 4646 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: June 2025. Ferlay J et al. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at: Accessed June 2025.. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
4 hours ago
- San Francisco Chronicle
UK, France and 23 other countries say the war in Gaza ‘must end now'
LONDON (AP) — Twenty-five countries including Britain, France and a host of European nations issued a joint statement on Monday saying the war in Gaza 'must end now' and Israel must comply with international law. The foreign ministers of countries including Australia, Canada and Japan said 'the suffering of civilians in Gaza has reached new depths' and condemned 'the drip feeding of aid and the inhumane killing of civilians, including children, seeking to meet their most basic needs of water and food." 'The Israeli government's aid delivery model is dangerous, fuels instability and deprives Gazans of human dignity,' the statement said. 'The Israeli government's denial of essential humanitarian assistance to the civilian population is unacceptable. Israel must comply with its obligations under international humanitarian law," it added. The signatories included the foreign ministers of about 20 European countries as well as Canada, Australia and New Zealand, and the EU commissioner for equality, preparedness and crisis management. The U.S. and Germany did not sign the statement. The signatories called for an immediate ceasefire, adding they are prepared to take action to support a political pathway to peace in the region. Gaza's population of more than 2 million Palestinians is in a catastrophic humanitarian crisis, now relying largely on the limited aid allowed into the territory. Many people have been displaced multiple times. Hamas triggered the war when militants stormed into southern Israel on Oct. 7, 2023, killing around 1,200 people and taking 251 others hostage. Fifty remain in Gaza, but fewer than half are thought to be alive. Israel's military offensive has killed more than 59,000 Palestinians, according to Gaza's Health Ministry. Its count doesn't distinguish between militants and civilians but the ministry says more than half of the dead are women and children. The ministry is part of the Hamas government, but the U.N. and other international organizations see it as the most reliable source of data on casualties. Israel and Hamas have been holding ceasefire talks in Qatar. Israeli Prime Minister Benjamin Netanyahu has repeatedly asserted that expanding Israel's military operations in Gaza will pressure Hamas in negotiations.
